- STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drugBoehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.STAT · 1mo ago↗ source
- STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet endingYou're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.STAT · 1mo ago↗ source
- STAT+: Lilly shares safety, tolerability data on its next-gen obesity drugEli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.STAT · 1mo ago